TOSS, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.901
AS - Asia 8.500
EU - Europa 6.079
SA - Sud America 1.333
Continente sconosciuto - Info sul continente non disponibili 279
AF - Africa 258
OC - Oceania 56
Totale 30.406
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.513
SG - Singapore 2.447
CN - Cina 1.988
IT - Italia 1.801
GB - Regno Unito 1.100
VN - Vietnam 1.071
BR - Brasile 983
HK - Hong Kong 983
DE - Germania 574
SE - Svezia 555
BD - Bangladesh 485
IE - Irlanda 342
FI - Finlandia 332
RU - Federazione Russa 308
KR - Corea 277
FR - Francia 266
IN - India 248
CA - Canada 199
ID - Indonesia 195
TR - Turchia 129
UA - Ucraina 125
AR - Argentina 113
MX - Messico 111
NL - Olanda 105
JP - Giappone 99
IQ - Iraq 98
BG - Bulgaria 93
ES - Italia 76
PL - Polonia 72
ZA - Sudafrica 68
EC - Ecuador 59
CO - Colombia 58
PK - Pakistan 57
AU - Australia 51
MY - Malesia 51
EG - Egitto 48
TW - Taiwan 45
AT - Austria 44
LT - Lituania 44
AE - Emirati Arabi Uniti 39
MA - Marocco 35
VE - Venezuela 34
IR - Iran 31
CL - Cile 30
PH - Filippine 30
SA - Arabia Saudita 29
UZ - Uzbekistan 27
BE - Belgio 26
KE - Kenya 25
PY - Paraguay 24
CZ - Repubblica Ceca 20
JO - Giordania 20
NP - Nepal 18
NO - Norvegia 17
TH - Thailandia 17
AZ - Azerbaigian 16
DK - Danimarca 16
HU - Ungheria 15
IL - Israele 15
MD - Moldavia 15
SI - Slovenia 15
CH - Svizzera 14
CR - Costa Rica 14
GR - Grecia 14
TN - Tunisia 14
BO - Bolivia 13
DZ - Algeria 12
PA - Panama 12
RO - Romania 12
AL - Albania 11
DO - Repubblica Dominicana 10
HR - Croazia 10
JM - Giamaica 10
PE - Perù 10
RS - Serbia 10
SY - Repubblica araba siriana 10
KG - Kirghizistan 9
KZ - Kazakistan 8
LB - Libano 8
LV - Lettonia 8
OM - Oman 8
PT - Portogallo 8
CI - Costa d'Avorio 7
CY - Cipro 7
ET - Etiopia 7
MT - Malta 7
UY - Uruguay 7
AO - Angola 6
BH - Bahrain 6
BY - Bielorussia 6
GE - Georgia 6
EU - Europa 5
GH - Ghana 5
HN - Honduras 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
SN - Senegal 5
XK - ???statistics.table.value.countryCode.XK??? 5
CG - Congo 4
GT - Guatemala 4
Totale 30.054
Salva come PNG Salva come JPEG
Città #
Ashburn 1.749
Singapore 1.418
Santa Clara 1.352
Fairfield 1.115
Hong Kong 953
San Jose 759
Chandler 751
Hefei 669
Woodbridge 537
Seattle 477
Houston 430
Southend 395
Cambridge 390
Council Bluffs 385
Beijing 364
Ho Chi Minh City 342
Dublin 337
Nyköping 336
London 332
Wilmington 332
Los Angeles 286
Dallas 277
Helsinki 260
New York 259
Seoul 258
Hanoi 249
Dearborn 212
Modena 207
Ann Arbor 206
Chicago 186
Milan 173
The Dalles 164
Jakarta 138
Lauterbourg 123
Bologna 112
Jacksonville 107
San Diego 107
Princeton 95
São Paulo 93
Munich 90
Sofia 90
Moscow 89
Buffalo 83
Tokyo 83
Boardman 82
Rome 82
Shanghai 76
Frankfurt am Main 75
Orem 73
Salt Lake City 67
Bremen 58
Eugene 52
Izmir 52
Warsaw 52
Baghdad 51
Da Nang 51
Haiphong 50
Redwood City 49
Fremont 44
Phoenix 43
Manchester 42
Montreal 40
Reggio Emilia 40
Toronto 40
Columbus 39
Kent 39
Nuremberg 39
Dong Ket 38
Brooklyn 37
Atlanta 36
Johannesburg 36
Guangzhou 35
Mexico City 35
Chennai 33
Rio de Janeiro 33
Portsmouth 32
Belo Horizonte 31
Lappeenranta 31
Parma 31
Redondo Beach 31
Stockholm 31
Denver 30
Mumbai 30
Naples 30
Florence 29
San Giuliano Milanese 28
Dhaka 27
Düsseldorf 27
Poplar 27
Turku 26
Falls Church 25
Miami 25
Sydney 25
Madrid 24
Miano 24
Tashkent 23
Vienna 23
Amsterdam 22
Boston 22
Brasília 22
Totale 19.565
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 630
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 485
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 476
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 455
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 425
Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: Hybrid Posters 411
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 398
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 392
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 366
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 364
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 353
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 345
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 344
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 343
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 339
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 330
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 325
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 313
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 308
NUT midline carcinoma of the head and neck: current perspectives 306
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 304
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 302
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 299
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 291
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 291
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 291
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 289
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study 288
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 288
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 287
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 283
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 283
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 280
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 278
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 274
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 274
Hereditary ovarian cancers: State of the art 270
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 269
Combined hormonal contraceptives in BRCA gene mutation carriers: why not? 265
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 260
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 254
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 253
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 253
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 252
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 251
Characterization of new ATM deletion associated with hereditary breast cancer 244
Twenty-years experience with de novo metastatic breast cancer 243
Chemoprevention strategies for high risk women 243
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 241
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 241
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 240
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 239
The role of exosomes in breast cancer diagnosis 239
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 237
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study 234
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 234
Radiological screening programs for women at high risk of developing breast cancer 229
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 228
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 228
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis 227
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 226
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 226
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial 225
Molecular characterization and targeted therapeutic approaches in breast cancer 221
Breast ultrasound in high-risk women 221
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 218
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 218
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 217
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 216
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 212
PARP Inhibitors for Breast Cancer Treatment A Review 212
PARP inhibitors for the treatment of ovarian cancer 207
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 200
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 197
Management of PALB2-associated breast cancer: A literature review and case report 194
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 194
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 194
Personalized Systemic Therapies in Hereditary Cancer Syndromes 192
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 191
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 189
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 189
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less 187
COVID-related disruption in mammographic screening: a year later. 181
Occult breast cancer: the uncommon presentation of a common disease 181
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 174
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group 174
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 173
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 171
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 171
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 169
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 168
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 165
A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer 165
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer 161
LOW-FREQUENCY ALLELE VARIANTS IN NGS MULTI-GENE PANELS FOR HEREDITARY CANCER TESTING: ARTIFACTS, CHIP OR MOSAICS? MANAGING THE RESULTS IN THE LABORATORY ROUTINE 159
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 157
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 157
The spectrum of fancm protein truncating variants in European breast cancer cases 155
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 154
Totale 25.853
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.186
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.887 123 164 141 82 68 133 90 102 250 164 336 234
2022/20232.396 268 301 169 192 225 259 48 180 526 35 98 95
2023/20241.756 92 92 97 175 260 144 230 229 68 69 114 186
2024/20255.933 141 59 120 302 986 765 584 372 703 389 644 868
2025/202612.860 900 476 1.134 1.391 1.504 824 1.575 708 1.232 1.257 1.077 782
2026/2027441 441 0 0 0 0 0 0 0 0 0 0 0
Totale 30.406